
Gilead Gets Analyst Thumbs Up On Market Potential Of HIV-Prevention Injection, But Retail’s Not Ready To Cheer Yet
Needham on Friday upgraded Gilead Sciences, Inc. (GILD) to ‘Buy’ from ‘Hold’ as it is confident that the company’s HIV prevention injection Lenacapavir could be a multi-billion dollar contributor to sales growth over the next few years. The firm has a $133 …